John Thompson

Title: John Thompson: Innovator in Monoclonal Antibodies

Introduction

John Thompson is a notable inventor based in Freiburg, Germany. He has made significant contributions to the field of medical research, particularly in the development of monoclonal antibodies. His work focuses on combating hepatitis C virus (HCV) infections, which pose a serious health threat worldwide.

Latest Patents

Thompson holds a patent for "Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis C virus infection." This invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface. By doing so, these antibodies inhibit HCV entry into susceptible cells, thereby preventing HCV infection. The patent also includes hybridoma cell lines that produce these monoclonal antibodies, as well as pharmaceutical compositions that incorporate them. Methods for treating or preventing HCV infection through the administration of these antibodies are also described in the patent.

Career Highlights

Throughout his career, John Thompson has worked with prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Strasbourg. His research has been pivotal in advancing our understanding of HCV and developing effective treatments.

Collaborations

Thompson has collaborated with esteemed colleagues, including Thomas Baumert and Catherine Schuster. Their combined expertise has contributed to the success of his research endeavors.

Conclusion

John Thompson's innovative work in the field of monoclonal antibodies represents a significant advancement in the fight against hepatitis C virus infections. His contributions continue to impact medical research and treatment options for patients worldwide.